{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T19:04:51Z","timestamp":1792695891457,"version":"4.5.0"},"reference-count":116,"publisher":"Elsevier BV","issue":"1-2","license":[{"start":{"date-parts":[[2009,8,1]],"date-time":"2009-08-01T00:00:00Z","timestamp":1249084800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2009,8]]},"DOI":"10.1016\/j.jns.2009.02.326","type":"journal-article","created":{"date-parts":[[2009,3,6]],"date-time":"2009-03-06T10:19:17Z","timestamp":1236334757000},"page":"21-27","source":"Crossref","is-referenced-by-count":114,"title":["The role of kynurenines in disorders of the central nervous system: Possibilities for neuroprotection"],"prefix":"10.1016","volume":"283","author":[{"given":"Eniko","family":"Vamos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arpad","family":"Pardutz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Klivenyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jozsef","family":"Toldi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laszlo","family":"Vecsei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2009.02.326_bib1","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1073\/pnas.33.6.155","article-title":"Kynurenine as an intermediate in the formation of nicotinic acid from tryptophane by neurospora","volume":"33","author":"Beadle","year":"1947","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jns.2009.02.326_bib2","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/978-1-4615-0135-0_12","article-title":"Expression of the kynurenine pathway enzymes in human microglia and macrophages","volume":"527","author":"Guillemin","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jns.2009.02.326_bib3","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1046\/j.1471-4159.2001.00498.x","article-title":"Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection","volume":"78","author":"Guillemin","year":"2001","journal-title":"J Neurochem"},{"key":"10.1016\/j.jns.2009.02.326_bib4","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1111\/j.1471-4159.1991.tb03460.x","article-title":"Blood-brain barrier transport of kynurenines: implications for brain synthesis and metabolism","volume":"56","author":"Fukui","year":"1991","journal-title":"J Neurochem"},{"key":"10.1016\/j.jns.2009.02.326_bib5","doi-asserted-by":"crossref","unstructured":"Riederer, P., Kruzik, P., Kienzl, E., Kleinberger, G., Jellinger, K., and Wesemann, W. Central aminergic function and its disturbance by hepatic disease: the current status of l-valine pharmacotherapy in metabolic coma. 1981;143\u2013182.","DOI":"10.1007\/978-1-349-05932-4_13"},{"key":"10.1016\/j.jns.2009.02.326_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1007\/BF01262727","article-title":"Stimulant and convulsive effects of kynurenines injected into brain ventricles in mice","volume":"42","author":"Lapin","year":"1978","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2009.02.326_bib7","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1046\/j.1471-4159.1997.69041519.x","article-title":"Species heterogeneity between gerbils and rats: quinolinate production by microglia and astrocytes and accumulations in response to ischemic brain injury and systemic immune activation","volume":"69","author":"Heyes","year":"1997","journal-title":"J Neurochem"},{"key":"10.1016\/j.jns.2009.02.326_bib8","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1111\/j.1471-4159.1993.tb07443.x","article-title":"Kynurenine pathway enzymes in brain: responses to ischemic brain injury versus systemic immune activation","volume":"61","author":"Saito","year":"1993","journal-title":"J Neurochem"},{"key":"10.1016\/j.jns.2009.02.326_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0014-2999(91)90436-T","article-title":"Comparative behavioral and pharmacological studies with centrally administered kynurenine and kynurenic acid in rats","volume":"196","author":"Vecsei","year":"1991","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jns.2009.02.326_bib10","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S0006-291X(02)02917-0","article-title":"Electrochemical and in vitro evaluation of the redox-properties of kynurenine species","volume":"300","author":"Giles","year":"2003","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jns.2009.02.326_bib11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.ejphar.2007.02.029","article-title":"Neuroprotective effect of L-kynurenine sulfate administered before focal cerebral ischemia in mice and global cerebral ischemia in gerbils","volume":"564","author":"Gigler","year":"2007","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jns.2009.02.326_bib12","first-page":"443","article-title":"Endogenous level of kynurenic acid and activities of kynurenine aminotransferases following transient global ischemia in the gerbil hippocampus","volume":"55","author":"Luchowska","year":"2003","journal-title":"Pol J Pharmacol"},{"key":"10.1016\/j.jns.2009.02.326_bib13","doi-asserted-by":"crossref","first-page":"5383","DOI":"10.1523\/JNEUROSCI.13-12-05383.1993","article-title":"Effects of the excitatory amino acid receptor antagonists kynurenate and indole-2-carboxylic acid on behavioral and neurochemical outcome following experimental brain injury","volume":"13","author":"Smith","year":"1993","journal-title":"J Neurosci"},{"key":"10.1016\/j.jns.2009.02.326_bib14","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1111\/j.1471-4159.1991.tb03783.x","article-title":"Measurement of rat brain kynurenine aminotransferase at physiological kynurenine concentrations","volume":"57","author":"Okuno","year":"1991","journal-title":"J Neurochem"},{"key":"10.1016\/j.jns.2009.02.326_bib15","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.biopsych.2004.06.006","article-title":"Endogenous kynurenic acid disrupts prepulse inhibition","volume":"56","author":"Erhardt","year":"2004","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jns.2009.02.326_bib16","first-page":"741","article-title":"Deficit of endogenous kynurenic acid in the frontal cortex of rats with a genetic form of absence epilepsy","volume":"55","author":"Kaminski","year":"2003","journal-title":"Pol J Pharmacol"},{"key":"10.1016\/j.jns.2009.02.326_bib17","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S0301-0082(00)00032-0","article-title":"Kynurenines in the CNS: from endogenous obscurity to therapeutic importance","volume":"64","author":"Stone","year":"2001","journal-title":"Prog Neurobiol"},{"key":"10.1016\/j.jns.2009.02.326_bib18","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1515\/CCLM.2003.129","article-title":"Tryptophan metabolites and brain disorders","volume":"41","author":"Stone","year":"2003","journal-title":"Clin Chem Lab Med"},{"key":"10.1016\/j.jns.2009.02.326_bib19","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/S0014-2999(99)00196-X","article-title":"Tryptophan metabolism and brain function: focus on kynurenine and other indole metabolites","volume":"375","author":"Moroni","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jns.2009.02.326_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.102.034439","article-title":"Manipulation of brain kynurenines: glial targets, neuronal effects, and clinical opportunities","volume":"303","author":"Schwarcz","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jns.2009.02.326_bib21","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1007\/978-1-4419-8969-7_10","article-title":"Kynurenines in neurodegenerative disorders: therapeutic consideration","volume":"541","author":"Klivenyi","year":"2004","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jns.2009.02.326_bib22","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/0304-3940(83)90115-5","article-title":"Differential vulnerability of central neurons of the rat to quinolinic acid","volume":"38","author":"Schwarcz","year":"1983","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jns.2009.02.326_bib23","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/0024-3205(84)90148-6","article-title":"Excitotoxic models for neurodegenerative disorders","volume":"35","author":"Schwarcz","year":"1984","journal-title":"Life Sci"},{"key":"10.1016\/j.jns.2009.02.326_bib24","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/0014-2999(81)90587-2","article-title":"Quinolinic acid: a potent endogenous excitant at amino acid receptors in CNS","volume":"72","author":"Stone","year":"1981","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jns.2009.02.326_bib25","doi-asserted-by":"crossref","first-page":"3857","DOI":"10.1046\/j.1460-9568.1999.00806.x","article-title":"3-Hydroxykynurenine potentiates quinolinate but not NMDA toxicity in the rat striatum","volume":"11","author":"Guidetti","year":"1999","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.jns.2009.02.326_bib26","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1046\/j.1471-4159.1998.70010299.x","article-title":"3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity","volume":"70","author":"Okuda","year":"1998","journal-title":"J Neurochem"},{"key":"10.1016\/j.jns.2009.02.326_bib27","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/0378-4347(91)80406-3","article-title":"Determination of 3-hydroxykynurenine in human brain and plasma by high-performance liquid chromatography with electrochemical detection. Increased concentrations in hepatic encephalopathy","volume":"565","author":"Pearson","year":"1991","journal-title":"J Chromatogr"},{"key":"10.1016\/j.jns.2009.02.326_bib28","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0304-3940(92)90749-W","article-title":"Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease","volume":"144","author":"Pearson","year":"1992","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jns.2009.02.326_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.jns.2005.07.006","article-title":"Kynurenine metabolism in plasma and in red blood cells in Parkinson's disease","volume":"239","author":"Hartai","year":"2005","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jns.2009.02.326_bib30","doi-asserted-by":"crossref","first-page":"1702","DOI":"10.1212\/WNL.42.9.1702","article-title":"Kynurenine pathway abnormalities in Parkinson's disease","volume":"42","author":"Ogawa","year":"1992","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2009.02.326_bib31","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0304-3940(95)11324-P","article-title":"Frontal cortex indoleamine-2,3-dioxygenase activity is increased in HIV-1-associated dementia","volume":"187","author":"Sardar","year":"1995","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jns.2009.02.326_bib32","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/978-1-4615-4709-9_69","article-title":"l-tryptophan-kynurenine pathway metabolite 3-hydroxyanthranilic acid induces apoptosis in macrophage-derived cells under pathophysiological conditions","volume":"467","author":"Morita","year":"1999","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jns.2009.02.326_bib33","doi-asserted-by":"crossref","first-page":"12553","DOI":"10.1073\/pnas.93.22.12553","article-title":"Hydrogen peroxide-mediated neuronal cell death induced by an endogenous neurotoxin, 3-hydroxykynurenine","volume":"93","author":"Okuda","year":"1996","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jns.2009.02.326_bib34","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/0006-8993(92)90883-B","article-title":"Uptake of 3-hydroxykynurenine measured in rat brain slices and in a neuronal cell line","volume":"584","author":"Eastman","year":"1992","journal-title":"Brain Res"},{"key":"10.1016\/j.jns.2009.02.326_bib35","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1002\/(SICI)1097-4547(19971101)50:3<457::AID-JNR12>3.0.CO;2-3","article-title":"Characterization of rat brain kynurenine aminotransferases I and II","volume":"50","author":"Guidetti","year":"1997","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.jns.2009.02.326_bib36","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/0165-6147(90)90238-4","article-title":"Excitatory amino acid receptors in epilepsy","volume":"11","author":"Dingledine","year":"1990","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.jns.2009.02.326_bib37","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1523\/JNEUROSCI.08-01-00185.1988","article-title":"Pharmacology of glutamate neurotoxicity in cortical cell culture: attenuation by NMDA antagonists","volume":"8","author":"Choi","year":"1988","journal-title":"J Neurosci"},{"key":"10.1016\/j.jns.2009.02.326_bib38","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1159\/000017338","article-title":"Metabolic control of kynurenic acid formation in the rat brain","volume":"20","author":"Hodgkins","year":"1998","journal-title":"Dev Neurosci"},{"key":"10.1016\/j.jns.2009.02.326_bib39","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1523\/JNEUROSCI.10-09-02965.1990","article-title":"Cerebral synthesis and release of kynurenic acid: an endogenous antagonist of excitatory amino acid receptors","volume":"10","author":"Swartz","year":"1990","journal-title":"J Neurosci"},{"key":"10.1016\/j.jns.2009.02.326_bib40","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1111\/j.1471-4159.1989.tb01881.x","article-title":"A glycine site associated with N-methyl-d-aspartic acid receptors: characterization and identification of a new class of antagonists","volume":"52","author":"Kessler","year":"1989","journal-title":"J Neurochem"},{"key":"10.1016\/j.jns.2009.02.326_bib41","doi-asserted-by":"crossref","first-page":"7463","DOI":"10.1523\/JNEUROSCI.21-19-07463.2001","article-title":"The brain metabolite kynurenic acid inhibits alpha7 nicotinic receptor activity and increases non-alpha7 nicotinic receptor expression: physiopathological implications","volume":"21","author":"Hilmas","year":"2001","journal-title":"J Neurosci"},{"key":"10.1016\/j.jns.2009.02.326_bib42","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1016\/j.bbr.2006.03.006","article-title":"Increased concentration of cerebral kynurenic acid alters stimulus processing and conditioned responding","volume":"170","author":"Chess","year":"2006","journal-title":"Behav Brain Res"},{"key":"10.1016\/j.jns.2009.02.326_bib43","doi-asserted-by":"crossref","first-page":"1454","DOI":"10.1038\/sj.npp.1300188","article-title":"Micromolar brain levels of kynurenic acid are associated with a disruption of auditory sensory gating in the rat","volume":"28","author":"Shepard","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jns.2009.02.326_bib44","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1002\/neu.10146","article-title":"Unconventional ligands and modulators of nicotinic receptors","volume":"53","author":"Pereira","year":"2002","journal-title":"J Neurobiol"},{"key":"10.1016\/j.jns.2009.02.326_bib45","doi-asserted-by":"crossref","first-page":"2141","DOI":"10.1046\/j.0953-816x.2001.01592.x","article-title":"Presynaptic kynurenate-sensitive receptors inhibit glutamate release","volume":"13","author":"Carpenedo","year":"2001","journal-title":"Eur J Neurosci"},{"key":"10.1016\/j.jns.2009.02.326_bib46","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.neulet.2006.03.051","article-title":"Kynurenic acid has a dual action on AMPA receptor responses","volume":"402","author":"Prescott","year":"2006","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jns.2009.02.326_bib47","doi-asserted-by":"crossref","unstructured":"Rozsa, E., Robotka, H., Vecsei, L., and Toldi, J. The Janus-faced kynurenic acid. J Neural Transm. 2008 in press.","DOI":"10.1007\/s00702-008-0052-5"},{"key":"10.1016\/j.jns.2009.02.326_bib48","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/s007020050029","article-title":"Tryptophan degradation and immune activation in Alzheimer's disease","volume":"107","author":"Widner","year":"2000","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2009.02.326_bib49","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/s007020050149","article-title":"Kynurenine metabolism in Alzheimer's disease","volume":"106","author":"Baran","year":"1999","journal-title":"J Neural Transm"},{"issue":"Pt 5","key":"10.1016\/j.jns.2009.02.326_bib50","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1093\/brain\/115.5.1249","article-title":"Quinolinic acid and kynurenine pathway metabolism in inflammatory and non-inflammatory neurological disease","volume":"115","author":"Heyes","year":"1992","journal-title":"Brain"},{"key":"10.1016\/j.jns.2009.02.326_bib51","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1016\/j.neuint.2006.08.012","article-title":"Decreased serum and red blood cell kynurenic acid levels in Alzheimer's disease","volume":"50","author":"Hartai","year":"2007","journal-title":"Neurochem Int"},{"key":"10.1016\/j.jns.2009.02.326_bib52","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1179\/135100002125000550","article-title":"Implications of the kynurenine pathway and quinolinic acid in Alzheimer's disease","volume":"7","author":"Guillemin","year":"2002","journal-title":"Redox Rep"},{"key":"10.1016\/j.jns.2009.02.326_bib53","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1007\/BF01739651","article-title":"Brain quinolinic acid in Alzheimer's dementia","volume":"239","author":"Sofic","year":"1989","journal-title":"Eur Arch Psychiatry Neurol Sci"},{"key":"10.1016\/j.jns.2009.02.326_bib54","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.mam.2004.02.013","article-title":"Molecular bases of the treatment of Alzheimer's disease with antioxidants: prevention of oxidative stress","volume":"25","author":"Vina","year":"2004","journal-title":"Mol Aspects Med"},{"key":"10.1016\/j.jns.2009.02.326_bib55","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S0197-4580(01)00327-X","article-title":"The effect of increased concentrations of homocysteine on the concentration of (E)-4-hydroxy-2-nonenal in the plasma and cerebrospinal fluid of patients with Alzheimer's disease","volume":"23","author":"Selley","year":"2002","journal-title":"Neurobiol Aging"},{"key":"10.1016\/j.jns.2009.02.326_bib56","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1007\/978-1-4615-0135-0_19","article-title":"Quinolinic acid in the pathogenesis of Alzheimer's disease","volume":"527","author":"Guillemin","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jns.2009.02.326_bib57","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1111\/j.1365-2990.2005.00655.x","article-title":"Indoleamine 2,3 dioxygenase and quinolinic acid immunoreactivity in Alzheimer's disease hippocampus","volume":"31","author":"Guillemin","year":"2005","journal-title":"Neuropathol Appl Neurobiol"},{"key":"10.1016\/j.jns.2009.02.326_bib58","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/0304-3940(86)90648-8","article-title":"Inhibition of excitatory neurotransmission with kynurenate reduces brain edema in neonatal anoxia","volume":"71","author":"Simon","year":"1986","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jns.2009.02.326_bib59","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/jcbfm.1992.57","article-title":"Neuroprotective effects of L-kynurenine on hypoxia-ischemia and NMDA lesions in neonatal rats","volume":"12","author":"Nozaki","year":"1992","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.jns.2009.02.326_bib60","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/ana.410220609","article-title":"Kynurenate inhibition of cell excitation decreases stroke size and deficits","volume":"22","author":"Germano","year":"1987","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2009.02.326_bib61","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/0304-3940(88)90813-0","article-title":"The excitatory amino acid antagonist kynurenic acid administered after hypoxic-ischemia in neonatal rats offers neuroprotection","volume":"90","author":"Andine","year":"1988","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jns.2009.02.326_bib62","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0006-8993(90)90997-P","article-title":"Kynurenate does not reduce infarct size after middle cerebral artery occlusion in spontaneously hypertensive rats","volume":"518","author":"Roussel","year":"1990","journal-title":"Brain Res"},{"key":"10.1016\/j.jns.2009.02.326_bib63","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00001756-199401120-00016","article-title":"Effect of kynurenic acid on the ischaemia-induced accumulation of glutamate in rat striatum","volume":"5","author":"Ghribi","year":"1994","journal-title":"Neuroreport"},{"key":"10.1016\/j.jns.2009.02.326_bib64","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0006-8993(94)91457-5","article-title":"Inhibition of the early phase of free fatty acid liberation during cerebral ischemia by excitatory amino acid antagonist administered by microdialysis","volume":"635","author":"Katayama","year":"1994","journal-title":"Brain Res"},{"key":"10.1016\/j.jns.2009.02.326_bib65","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1016\/S0278-5846(99)00032-9","article-title":"Brain concentrations of kynurenic acid after a systemic neuroprotective dose in the gerbil model of global ischemia","volume":"23","author":"Salvati","year":"1999","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.jns.2009.02.326_bib66","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1097\/00004647-199907000-00007","article-title":"Kynurenine hydroxylase inhibitors reduce ischemic brain damage: studies with (m-nitrobenzoyl)-alanine (mNBA) and 3,4-dimethoxy-[-N-4-(nitrophenyl)thiazol-2yl]-benzenesulfonamide (Ro 61-8048) in models of focal or global brain ischemia","volume":"19","author":"Cozzi","year":"1999","journal-title":"J Cereb Blood Flow Metab"},{"key":"10.1016\/j.jns.2009.02.326_bib67","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1046\/j.1471-4159.2002.01090.x","article-title":"Kynurenine 3-mono-oxygenase inhibitors attenuate post-ischemic neuronal death in organotypic hippocampal slice cultures","volume":"82","author":"Carpenedo","year":"2002","journal-title":"J Neurochem"},{"key":"10.1016\/j.jns.2009.02.326_bib68","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0022-510X(93)90285-7","article-title":"The possible contribution of microglia and macrophages to delayed neuronal death after ischemia","volume":"114","author":"Lees","year":"1993","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.jns.2009.02.326_bib69","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0169-328X(98)00136-3","article-title":"Temporal and spatial changes of quinolinic acid immunoreactivity in the gerbil hippocampus following transient cerebral ischemia","volume":"59","author":"Baratte","year":"1998","journal-title":"Brain Res Mol Brain Res"},{"key":"10.1016\/j.jns.2009.02.326_bib70","doi-asserted-by":"crossref","first-page":"1077","DOI":"10.1002\/jnr.21212","article-title":"Interleukin-1beta but not tumor necrosis factor-alpha potentiates neuronal damage by quinolinic acid: protection by an adenosine A2A receptor antagonist","volume":"85","author":"Stone","year":"2007","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.jns.2009.02.326_bib71","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/BF02259654","article-title":"Indoleamine concentrations in cerebrospinal fluid from patients with Alzheimer type and Binswanger type dementias before and after administration of citalopram, a synthetic serotonin uptake inhibitor","volume":"9","author":"Tohgi","year":"1995","journal-title":"J Neural Transm Park Dis Dement Sect"},{"key":"10.1016\/j.jns.2009.02.326_bib72","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/01.HYP.35.1.413","article-title":"Excitatory amino acids in the rostral ventrolateral medulla support blood pressure in spontaneously hypertensive rats","volume":"35","author":"Ito","year":"2000","journal-title":"Hypertension"},{"key":"10.1016\/j.jns.2009.02.326_bib73","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1291\/hypres.25.135","article-title":"Kynureninase is a novel candidate gene for hypertension in spontaneously hypertensive rats","volume":"25","author":"Mizutani","year":"2002","journal-title":"Hypertens Res"},{"key":"10.1016\/j.jns.2009.02.326_bib74","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S0306-4522(00)00504-2","article-title":"Kynurenine 3-mono-oxygenase activity and neurotoxic kynurenine metabolites increase in the spinal cord of rats with experimental allergic encephalomyelitis","volume":"102","author":"Chiarugi","year":"2001","journal-title":"Neuroscience"},{"key":"10.1016\/j.jns.2009.02.326_bib75","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/S0006-8993(01)02017-0","article-title":"Oligodendrocyte killing by quinolinic acid in vitro","volume":"896","author":"Cammer","year":"2001","journal-title":"Brain Res"},{"key":"10.1016\/j.jns.2009.02.326_bib76","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/S0304-3940(02)00710-3","article-title":"Decreased level of kynurenic acid in cerebrospinal fluid of relapsing-onset multiple sclerosis patients","volume":"331","author":"Rejdak","year":"2002","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.jns.2009.02.326_bib77","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1007\/s00702-007-0667-y","article-title":"Astrocytic activation in relation to inflammatory markers during clinical exacerbation of relapsing\u2013remitting multiple sclerosis","volume":"114","author":"Rejdak","year":"2007","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2009.02.326_bib78","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/j.1600-0404.2005.00442.x","article-title":"Kynurenine metabolism in multiple sclerosis","volume":"112","author":"Hartai","year":"2005","journal-title":"Acta Neurol Scand"},{"key":"10.1016\/j.jns.2009.02.326_bib79","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1111\/j.1468-1331.2005.01041.x","article-title":"Interferon-beta affects the tryptophan metabolism in multiple sclerosis patients","volume":"12","author":"Amirkhani","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jns.2009.02.326_bib80","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1089\/107999001317205231","article-title":"IFN-beta1b induces kynurenine pathway metabolism in human macrophages: potential implications for multiple sclerosis treatment","volume":"21","author":"Guillemin","year":"2001","journal-title":"J Interferon Cytokine Res"},{"key":"10.1016\/j.jns.2009.02.326_bib81","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.2042-7158.1990.tb05434.x","article-title":"Kynurenic acid blocks chemogenic nociception","volume":"42","author":"Hajos","year":"1990","journal-title":"J Pharm Pharmacol"},{"key":"10.1016\/j.jns.2009.02.326_bib82","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/0014-2999(92)90067-E","article-title":"Antinociceptive actions of different classes of excitatory amino acid receptor antagonists in mice","volume":"212","author":"Nasstrom","year":"1992","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jns.2009.02.326_bib83","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1111\/j.1476-5381.1991.tb12547.x","article-title":"Selective antagonism of capsaicin by capsazepine: evidence for a spinal receptor site in capsaicin-induced antinociception","volume":"104","author":"Dickenson","year":"1991","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.jns.2009.02.326_bib84","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1097\/00001756-199301000-00004","article-title":"Differential effects of NMDA and non-NMDA receptor antagonists on spinal cutaneous vs muscular nociception in the cat","volume":"4","author":"Song","year":"1993","journal-title":"Neuroreport"},{"key":"10.1016\/j.jns.2009.02.326_bib85","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/0006-8993(93)91571-9","article-title":"Electrophysiological characterization of the projection from the nucleus raphe magnus to the lateral reticular nucleus: possible role of an excitatory amino acid in synaptic activation","volume":"606","author":"Murphy","year":"1993","journal-title":"Brain Res"},{"key":"10.1016\/j.jns.2009.02.326_bib86","doi-asserted-by":"crossref","first-page":"8947","DOI":"10.1523\/JNEUROSCI.18-21-08947.1998","article-title":"Intradermal injection of capsaicin in humans produces degeneration and subsequent reinnervation of epidermal nerve fibers: correlation with sensory function","volume":"18","author":"Simone","year":"1998","journal-title":"J Neurosci"},{"key":"10.1016\/j.jns.2009.02.326_bib87","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1002\/ana.410330109","article-title":"The trigeminovascular system and migraine: studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats","volume":"33","author":"Goadsby","year":"1993","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2009.02.326_bib88","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1038\/nm0795-658","article-title":"Brain stem activation in spontaneous human migraine attacks","volume":"1","author":"Weiller","year":"1995","journal-title":"Nat Med"},{"key":"10.1016\/j.jns.2009.02.326_bib89","first-page":"133","article-title":"Genes, proteases, cortical spreading depression and migraine: impact on pathophysiology and treatment","volume":"22","author":"Moskowitz","year":"2007","journal-title":"Funct Neurol"},{"key":"10.1016\/j.jns.2009.02.326_bib90","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/j.expneurol.2003.12.001","article-title":"Kynurenine aminotransferase in the supratentorial dura mater of the rat: effect of stimulation of the trigeminal ganglion","volume":"186","author":"Knyihar-Csillik","year":"2004","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jns.2009.02.326_bib91","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00702-006-0545-z","article-title":"Kynurenine in combination with probenecid mitigates the stimulation-induced increase of c-fos immunoreactivity of the rat caudal trigeminal nucleus in an experimental migraine model","volume":"114","author":"Knyihar-Csillik","year":"2007","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2009.02.326_bib92","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0006-8993(92)90182-9","article-title":"Activation of locus coeruleus neurons by nucleus paragigantocellularis or noxious sensory stimulation is mediated by intracoerulear excitatory amino acid neurotransmission","volume":"598","author":"Ennis","year":"1992","journal-title":"Brain Res"},{"key":"10.1016\/j.jns.2009.02.326_bib93","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0304-3959(01)00348-7","article-title":"Physiological characteristics of the projection pathway from the medial preoptic to the nucleus raphe magnus of the rat and its modulation by the periaqueductal gray","volume":"94","author":"Jiang","year":"2001","journal-title":"Pain"},{"key":"10.1016\/j.jns.2009.02.326_bib94","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.brainres.2004.01.004","article-title":"Cortical spreading depression augments kynurenate levels and reduces malonate toxicity in the rat cortex","volume":"1002","author":"Kiss","year":"2004","journal-title":"Brain Res"},{"key":"10.1016\/j.jns.2009.02.326_bib95","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/0006-8993(88)90690-7","article-title":"Evidence for a role of the N-methyl-d-aspartate (NMDA) receptor in cortical spreading depression in the rat","volume":"457","author":"Marrannes","year":"1988","journal-title":"Brain Res"},{"key":"10.1016\/j.jns.2009.02.326_bib96","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0006-8993(97)00434-4","article-title":"Effects of probenecid on the elicitation of spreading depression in the rat striatum","volume":"764","author":"Taylor","year":"1997","journal-title":"Brain Res"},{"key":"10.1016\/j.jns.2009.02.326_bib97","doi-asserted-by":"crossref","first-page":"251","DOI":"10.2174\/187152707781387279","article-title":"The role of glutamate and its receptors in migraine","volume":"6","author":"Vikelis","year":"2007","journal-title":"CNS Neurol Disord Drug Targets"},{"key":"10.1016\/j.jns.2009.02.326_bib98","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S0022-3565(25)23251-7","article-title":"Kinetics of MK-801 and its effect on quinolinic acid-induced seizures and neurotoxicity in rats","volume":"249","author":"Vezzani","year":"1989","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.jns.2009.02.326_bib99","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/0091-3057(90)90391-T","article-title":"Inhibitory influence of excitatory amino acid antagonists on penicillin-induced epileptiform bursting in rat hippocampal slices","volume":"35","author":"Sagratella","year":"1990","journal-title":"Pharmacol Biochem Behav"},{"key":"10.1016\/j.jns.2009.02.326_bib100","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/0361-9230(92)90184-Y","article-title":"Kynurenine and probenecid inhibit pentylenetetrazol- and NMDLA-induced seizures and increase kynurenic acid concentrations in the brain","volume":"28","author":"Vecsei","year":"1992","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.jns.2009.02.326_bib101","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1016\/0361-9230(94)90236-4","article-title":"The WAG\/Rij rat model for nonconvulsive absence epilepsy: involvement of nonNMDA receptors","volume":"33","author":"Peeters","year":"1994","journal-title":"Brain Res Bull"},{"key":"10.1016\/j.jns.2009.02.326_bib102","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.ejphar.2006.05.015","article-title":"Enhancement of brain kynurenic acid production by anticonvulsants\u2014novel mechanism of antiepileptic activity?","volume":"541","author":"Kocki","year":"2006","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jns.2009.02.326_bib103","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/BF01252805","article-title":"Studies on kynurenine in human cerebrospinal fluid: lowered levels in epilepsy","volume":"58","author":"Young","year":"1983","journal-title":"J Neural Transm"},{"key":"10.1016\/j.jns.2009.02.326_bib104","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/0887-8994(94)90060-4","article-title":"Kynurenic acid is decreased in cerebrospinal fluid of patients with infantile spasms","volume":"10","author":"Yamamoto","year":"1994","journal-title":"Pediatr Neurol"},{"key":"10.1016\/j.jns.2009.02.326_bib105","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/0387-7604(95)00065-J","article-title":"Studies on cerebrospinal fluid kynurenic acid concentrations in epileptic children","volume":"17","author":"Yamamoto","year":"1995","journal-title":"Brain Dev"},{"key":"10.1016\/j.jns.2009.02.326_bib106","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/j.1528-1157.1994.tb02428.x","article-title":"Kynurenine pathway metabolites in cerebrospinal fluid and serum in complex partial seizures","volume":"35","author":"Heyes","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.jns.2009.02.326_bib107","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1212\/01.WNL.0000052682.99812.F5","article-title":"Alpha-[11C] methyl-l-tryptophan and glucose metabolism in patients with temporal lobe epilepsy","volume":"60","author":"Natsume","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2009.02.326_bib108","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0920-1211(02)00216-4","article-title":"alpha-[11C]-Methyl-l-tryptophan PET identifies the epileptogenic tuber and correlates with interictal spike frequency","volume":"52","author":"Fedi","year":"2003","journal-title":"Epilepsy Res"},{"key":"10.1016\/j.jns.2009.02.326_bib109","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1126\/science.6849138","article-title":"Quinolinic acid: an endogenous metabolite that produces axon-sparing lesions in rat brain","volume":"219","author":"Schwarcz","year":"1983","journal-title":"Science"},{"key":"10.1016\/j.jns.2009.02.326_bib110","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1111\/j.1471-4159.1988.tb02503.x","article-title":"Brain quinolinic acid in Huntington's disease","volume":"50","author":"Reynolds","year":"1988","journal-title":"J Neurochem"},{"key":"10.1016\/j.jns.2009.02.326_bib111","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1002\/ana.410240417","article-title":"Cerebrospinal fluid levels of quinolinic acid in Huntington's disease and schizophrenia","volume":"24","author":"Schwarcz","year":"1988","journal-title":"Ann Neurol"},{"key":"10.1016\/j.jns.2009.02.326_bib112","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/978-1-4615-0135-0_16","article-title":"3-Hydroxykynurenine and quinolinate: pathogenic synergism in early grade Huntington's disease?","volume":"527","author":"Guidetti","year":"2003","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.jns.2009.02.326_bib113","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.nbd.2006.02.011","article-title":"Elevated brain 3-hydroxykynurenine and quinolinate levels in Huntington disease mice","volume":"23","author":"Guidetti","year":"2006","journal-title":"Neurobiol Dis"},{"key":"10.1016\/j.jns.2009.02.326_bib114","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1111\/j.1471-4159.2005.03070.x","article-title":"Tryptophan metabolism and oxidative stress in patients with Huntington's disease","volume":"93","author":"Stoy","year":"2005","journal-title":"J Neurochem"},{"key":"10.1016\/j.jns.2009.02.326_bib115","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.expneurol.2005.07.004","article-title":"Endogenous kynurenate controls the vulnerability of striatal neurons to quinolinate: implications for Huntington's disease","volume":"197","author":"Sapko","year":"2006","journal-title":"Exp Neurol"},{"key":"10.1016\/j.jns.2009.02.326_bib116","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1007\/s007020200014","article-title":"Increased neopterin production and tryptophan degradation in advanced Parkinson's disease","volume":"109","author":"Widner","year":"2002","journal-title":"J Neural Transm"}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X09003748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X09003748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,8]],"date-time":"2025-02-08T01:55:44Z","timestamp":1738979744000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X09003748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,8]]},"references-count":116,"journal-issue":{"issue":"1-2","published-print":{"date-parts":[[2009,8]]}},"alternative-id":["S0022510X09003748"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2009.02.326","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2009,8]]}}}